Same Drug Class

Nivolumab vs Tofacitinib

Nivolumab vs Tofacitinib: Overview

This comparison examines the pharmacological differences between Nivolumab and Tofacitinib.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

Pharmacokinetics

Half-life: Nivolumab — 27 days; Tofacitinib — 3.2 hours.

Chemical Properties

Molecular Formula: Tofacitinib — C16H20N6O.

Molecular Weight: Tofacitinib — 312.3700 g/mol.

Type: Nivolumab — Antibody; Tofacitinib — Small molecule.